Atria Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Atria Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,499	Closed	-$370K	–	1911
2024 Q2	$370K	Buy	+4,499	New	+$375K	﹤0.01%	1461
2020 Q3	–	Sell	-9,545	Closed	-$1.18M	–	583
2020 Q2	$1.18M	Buy	9,545 +629	+7%	+$62.5K	0.04%	462
2020 Q1	$753K	Buy	8,916 +3,286	+58%	+$283K	0.06%	271
2019 Q4	$476K	Buy	5,630 +2,614	+87%	+$197K	0.01%	803
2019 Q3	$203K	Sell	3,016 -359	-11%	-$27.7K	0.01%	846
2019 Q2	$243K	Buy	3,375 +660	+24%	+$56.5K	0.01%	822
2019 Q1	$241K	Sell	2,715 -246	-8%	-$22.8K	0.01%	793
2018 Q4	$252K	Sell	2,961 -297	-9%	-$28.3K	0.01%	719
2018 Q3	$316K	Buy	3,258 +317	+11%	+$31.6K	0.01%	754
2018 Q2	$277K	Buy	+2,941	New	+$258K	0.01%	762

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Atria Investments's BMRN Position: Q3 2024 in Review

Atria Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 4,499 shares — an estimated $370K sold.

Atria Investments first reported a position in BMRN in Q2 2018 and held it in 10 quarters. The position peaked at $1.18M in Q2 2020. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Atria Investments reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Atria Investments sold 4,499 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $370K.
Atria Investments first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Atria Investments's BioMarin Pharmaceuticals position peaked at $1.18M in Q2 2020.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Atria Investments's 13F filing for Q3 2024, filed 1 Nov 2024.